{"title":"Bacterial community structure and dominant species in pharmaceutical manufacturing water revealed by high-throughput sequencing","authors":"Saori Shikama , Kimiko Uchii , Makoto Sadamitsu , Takashi Kaminagayoshi , Yoshihiko Koizumi , Masao Nasu","doi":"10.1016/j.ejps.2025.107153","DOIUrl":null,"url":null,"abstract":"<div><div>Control of the microbiological quality of water for pharmaceutical manufacturing is essential to ensure the safety of pharmaceutical products. A major issue in the quality control of pharmaceutical manufacturing water is the time required to identify microbial contaminants, which can be as long as several days using traditional culture methods. Here, we demonstrate the use of high-throughput sequencing of samples taken from a pharmaceutical water production system, using the Oxford Nanopore Technologies MinION sequencing platform. We successfully revealed the bacterial community structure and dominant species in stagnation sampling ports of the pharmaceutical water supply system. Dynamic changes in dominant bacteria were detected across different treatment stages: <em>Phreatobacter</em> in the city water, <em>Methylobacterium</em> in the reverse osmosis-treated water (>95 % of the bacterial abundance) and <em>Ralstonia</em> in the ultrafiltration-treated water (>93 % of the bacterial abundance). Compared with traditional culture methods, the MinION sequencing approach enabled rapid characterization of bacterial composition and prompt identification of dominant species. This cost-effective, molecular-based approach will usher in a new era of bioburden monitoring and identification in pharmaceutical water systems, in line with regulatory recommendations to implement rapid microbiological methods. Our findings demonstrate the practical application of high-throughput sequencing for comprehensive bacterial analysis in the pharmaceutical industry.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"211 ","pages":"Article 107153"},"PeriodicalIF":4.7000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928098725001526","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Control of the microbiological quality of water for pharmaceutical manufacturing is essential to ensure the safety of pharmaceutical products. A major issue in the quality control of pharmaceutical manufacturing water is the time required to identify microbial contaminants, which can be as long as several days using traditional culture methods. Here, we demonstrate the use of high-throughput sequencing of samples taken from a pharmaceutical water production system, using the Oxford Nanopore Technologies MinION sequencing platform. We successfully revealed the bacterial community structure and dominant species in stagnation sampling ports of the pharmaceutical water supply system. Dynamic changes in dominant bacteria were detected across different treatment stages: Phreatobacter in the city water, Methylobacterium in the reverse osmosis-treated water (>95 % of the bacterial abundance) and Ralstonia in the ultrafiltration-treated water (>93 % of the bacterial abundance). Compared with traditional culture methods, the MinION sequencing approach enabled rapid characterization of bacterial composition and prompt identification of dominant species. This cost-effective, molecular-based approach will usher in a new era of bioburden monitoring and identification in pharmaceutical water systems, in line with regulatory recommendations to implement rapid microbiological methods. Our findings demonstrate the practical application of high-throughput sequencing for comprehensive bacterial analysis in the pharmaceutical industry.
期刊介绍:
The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development.
More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making.
Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.